| niacin extended-release formulation / Generic mfg. |
NCT00376584: Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) |
|
|
| Completed | 3 | 825 | NA | MK-0524A, ER Niacin, Placebo | Merck Sharp & Dohme LLC | Hypercholesteremia, Hyperlipidemia | 01/07 | 01/07 | | |
NCT00378833: Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) |
|
|
| Completed | 3 | 1300 | NA | niacin (+) laropiprant, MK0524A, niacin | Merck Sharp & Dohme LLC | Hypercholesterolemia, Hyperlipidemia | 03/07 | 03/07 | | |
SUPREME, NCT00465088: An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia |
|
|
| Completed | 3 | 199 | US | Niacin ER/Simvastatin Tablets, ABT-919/483, Niacin ER/Simvastatin, Simcor, atorvastatin | Abbott | Hyperlipidemia, Mixed Dyslipidemia | 02/08 | | | |
ASA EFFECTS, NCT00626392: Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia |
|
|
| Completed | 3 | 277 | US | niacin extended-release (NER), Niaspan, aspirin (ASA), acetylsalicylic acid, aspirin placebo (ASA Pbo), placebo | Abbott | Dyslipidemia | 04/08 | 04/08 | | |
NCT00630877: Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin |
|
|
| Completed | 3 | 276 | US | Niacin extended-release (NER), ABT-919, Niaspan, Niacin extended-release (NER) placebo, Aspirin (ASA), acetylsalicylic acid, Aspirin (ASA) placebo | Abbott | Dyslipidemia | 06/08 | 06/08 | | |
NCT00479388: Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) |
|
|
| Completed | 3 | 1216 | Canada | Comparator: simvastatin, Zocor®, niacin (+) laropiprant, MK0524A, Comparator: atorvastatin calcium, atorvastatin | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Mixed Dyslipidemia | 07/08 | 10/08 | | |
NCT00664287: Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) |
|
|
| Withdrawn | 3 | 0 | US | niacin (+) laropiprant, MK0524A, placebo (unspecified) | Merck Sharp & Dohme LLC | Dyslipidemia | 11/09 | | | |
NCT00961636 / 2009-012772-27: A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) |
|
|
| Completed | 3 | 1152 | US | ER niacin (+) laropiprant (ERN/LRPT), Extended-release niacin (ERN), Placebo to ERN/LRPT | Merck Sharp & Dohme LLC | Dyslipidemia | 01/11 | 01/11 | | |
NCT01335997 / 2011-001007-12: Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) |
|
|
| Terminated | 3 | 1139 | NA | ER niacin/laropiprant (ERN/LRPT), MK-0524B, ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), MK-0524A, Tredaptive™, Simvastatin (SIM), Zocor®, Placebo Run-In, SIM-matching placebo | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Mixed Dyslipidemia | 01/12 | 01/12 | | |
NCT01294683 / 2010-023939-42: A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) |
|
|
| Terminated | 3 | 977 | NA | Simvastatin, Zocor, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), MK-0524B, Extended Release (ER) niacin/laropiprant (N/LRPT), MK-0524A, Placebo | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Dyslipidemia | 01/12 | 01/12 | | |
NCT00108485: Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy |
|
|
| Terminated | 3 | 9 | US | Extended release niacin, Niaspan, Placebo | University of Miami | Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia | 12/12 | 12/12 | | |
NCT01414166: Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) |
|
|
| Terminated | 3 | 244 | RoW | ERN/LRPT, Tredaptive™, placebo | Merck Sharp & Dohme LLC | Dyslipidemia | 02/13 | 02/13 | | |
MK-0524A-133, NCT01274559: Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels |
|
|
| Terminated | 3 | 1173 | NA | Extended-release niacin/laropiprant (ERN/LRPT), Placebo | Merck Sharp & Dohme LLC | Primary Hypercholesterolemia, Mixed Dyslipidemia | 02/13 | 02/13 | | |
